Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 15 Jul 2015

Rein David B, Wittenborn John S, Smith Bryce D, Liffmann Danielle K, Ward John W

Abstract excerpt

BACKGROUND: New hepatitis C virus (HCV) treatments deliver higher cure rates with fewer contraindications, increasing demand for treatment and healthcare costs. The cost-effectiveness of new treatments is unknown. METHODS: We conducted a microsimulation of guideline testing followed by alternative treatment regimens for HCV among the US population aged 20 and older to estimate cases identified, treated, sustained...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Markov Chains

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Polyethylene Glycols

Share to Quality-Adjusted Life Years

Share to Ribavirin

Share to Simeprevir

Share to Sofosbuvir

Share to Uridine Monophosphate

Source

Open in PubMed Open full text

Identifiers

PMID: 25778747
DOI: 10.1093/cid/civ220
PMCID: PMC5759765

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.PMID 25778747Read ↗

Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.Semantic proximity Read ↗

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.Semantic proximity Read ↗

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.Semantic proximity Read ↗

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.Semantic proximity Read ↗

Cost and cost-effectiveness of Hepatitis C virus self-testing in four settings: an economic evaluationSemantic proximity Read ↗

Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?Semantic proximity Read ↗

Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.Semantic proximity Read ↗

Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.Semantic proximity Read ↗

Cost effectiveness of hepatitis C direct acting agents.Semantic proximity Read ↗

Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.Semantic proximity Read ↗

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling studySemantic proximity Read ↗

Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.